HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians

被引:16
|
作者
Ingiliz, Patrick [1 ]
Rockstroh, Juergen K. [2 ]
机构
[1] Med Ctr Infect Dis Berlin, Berlin, Germany
[2] Univ Bonn, Dept Med 1, Bonn, Germany
关键词
boceprevir; DAA; HIV-HCV co-infection; liver fibrosis; telaprevir; HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; GENOTYPE; INFECTION; LIVER FIBROSIS; PLUS RIBAVIRIN; TRANSIENT ELASTOGRAPHY; PEGYLATED INTERFERON; POSITIVE INDIVIDUALS; THERAPY; BIOPSY;
D O I
10.1111/j.1478-3231.2012.02796.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
With the licensing of the first hepatitis C (HCV) protease inhibitors (PI), telaprevir (TVR) and boceprevir (BOC), cure rates for chronic HCV infection will substantially improve. Human immunodeficiency virus-chronic hepatitis C (HIV-HCV) co-infected patients are in urgent need for these new drugs, because they are facing both severe liver disease and lower response rates than HCV monoinfected patients. The currently available efficacy data are however, limited to two phase II trials. Fortunately, TVR and BOC appear to be able to improve cure rates in co-infected patients. A major challenge for clinicians will be the management of drug-drug interactions of antiretroviral drugs and new PI. As HCV PI are also metabolized by the cytochrome P450 3A4 system interactions are probable as well with non-nucleoside reverse transcriptase inhibitors as with HIV PI. To our knowledge, TVR can only be safely used with one protease inhibitor, boosted atazanavir, and also with efavirenz (EFV), although this combination requires TVR dose adjustments. Boceprevir should not be combined with HIV PI and should not be combined with EFV. The approval of TVR and BOC will create new chances of cure also for HIV-HCV co-infected patients. However, the decision who to treat or not has to be taken carefully on the basis of fibrosis stage and previous treatment outcomes. In addition, HIV therapy needs to be optimized according to the available drug-drug interaction data.
引用
收藏
页码:1194 / 1199
页数:6
相关论文
共 50 条
  • [41] HIV/HCV co-infection: clinical and therapeutic challenges
    Ensoli, F
    Sirianni, MC
    AIDS, 2002, 16 (10) : 1419 - 1420
  • [42] Micro-elimination of HIV and HCV co-infection
    Dusheiko, Geoff
    Childs, Kate
    LANCET HIV, 2020, 8 (02): : e61 - e62
  • [43] Markers of iron metabolism in HIV/HCV co-infection
    Childs, K.
    Carey, I.
    Cannon, M.
    HIV MEDICINE, 2020, 21 : 50 - 50
  • [44] Pathogenesis of Accelerated Fibrosis in HIV/HCV Co-infection
    Lin, Wenyu
    Weinberg, Ethan M.
    Chung, Raymond T.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 207 : S13 - S18
  • [45] UNITAID can address HCV/HIV co-infection
    von Schoen-Angerer, Tido
    Cohn, Jennifer
    Swan, Tracy
    Piot, Peter
    LANCET, 2013, 381 (9867): : 628 - 628
  • [46] Increased CD56bright NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype
    Suvercha Bhardwaj
    Fareed Ahmad
    Heiner Wedemeyer
    Marcus Cornberg
    Julian Schulze zur Wiesch
    Jan van Lunzen
    Shiv K. Sarin
    Reinhold E. Schmidt
    Dirk Meyer-Olson
    Virology Journal, 13
  • [47] Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection
    Ragni, M. V.
    Nalesnik, M. A.
    Schillo, R.
    Dang, Q.
    HAEMOPHILIA, 2009, 15 (02) : 552 - 558
  • [48] Increased CD56bright NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype
    Bhardwaj, Suvercha
    Ahmad, Fareed
    Wedemeyer, Heiner
    Cornberg, Marcus
    zur Wiesch, Julian Schulze
    van Lunzen, Jan
    Sarin, Shiv K.
    Schmidt, Reinhold E.
    Meyer-Olson, Dirk
    VIROLOGY JOURNAL, 2016, 13
  • [49] Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis
    McLinden, Taylor
    Moodie, Erica E. M.
    Hamelin, Anne-Marie
    Harper, Sam
    Rossi, Carmine
    Walmsley, Sharon L.
    Rourke, Sean B.
    Cooper, Curtis
    Klein, Marina B.
    Cox, Joseph
    DRUG AND ALCOHOL DEPENDENCE, 2018, 185 : 374 - 380
  • [50] Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection
    Dutoit, V
    Ciuffreda, D
    Comte, D
    Gonvers, JJ
    Pantaleo, G
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (12) : 3493 - 3504